Kossan briefing update from RHB Research
{{{PM me to join GLOVE Private Discussion Room}}}
I invite you to read my blog and make a smart GLOVE decision.
https://klse.i3investor.com/blogs/gloveharicut/blidx.jsp
I am not sure the vaccine is useful or not. CEO have better answer.
Do you have to wear GLOVES to give a vaccine shot?
I am holding my GLOVES. I will only sell when ASP come down but not stock price come down.
I buy vaccine logistic by using the GLOVEs profit as hedging to vaccine news.
How to distribute the ultra-cold vaccine? I am allocating my GLOVE profit to TASCO Cold Chain to hedge vaccine news
How to distribute the ultra-cold vaccine? I am allocating my GLOVE profit to FREIGHT to hedge vaccine news
KGB's dry ice plant to flourish from Pfizer's vaccine success?
I am reproducing the RHB Research update to my blog.
This post don't have any value added content.
Compile here for my own record.
Please skip if you don't like it.
*Kossan briefing update*
*1. 427 workers are COVID-19 positive.* Kossan shared that 427 of its employees are tested positive. Note that Kossan has started testing its 7004 workers from 4-10 December.
*2. Action taken by Kossan* The Company has transported the positive cases to hospitals as per Ministry of Health’s instruction. A thorough disinfection of all areas where the affected individuals have been present has also been carried out. For those under quarantine due to close contact, a second PCR test will be done on 16 and 17 Dec with the result to be known on 18-Dec.
*3. Plans to test 20% of its workers every 2 weeks going forward*. The Company believes that this is necessary as all of its employees who are tested COVID-19 positive are asymptomatic.
*4. Accommodation space for workers exceed ILO standard* Kossan shared that its average accommodation space per worker is 46 sq ft. This is above the requirement of 38.75 sq ft per worker set by International Labour Organization (ILO).
*5. About 1% of total annual output volume affected*. 25% if its capacity is affected for 2 weeks. This works out to be around 0.96% of total annual output. Earnings impact is estimated to be around 2% of FY20 earnings.
*RHB Research*
Market Buzz
Be the first to like this.
calvintaneng KOSSAN IS NOW THE CHEAPEST AND BEST BUY AMONG ALL GENUINE MEDICAL GLOVE STOCKS
15/12/2020 3:00 PM
paperplane *ASP updates*
3Q20: USD31/k pcs (+40-42% QoQ)
4Q20E: USD50-60/k pcs (+77% QoQ) - ASP from management
1Q20E: USD80/k pcs (+33-60% QoQ) - ASP from management
15/12/2020 3:01 PM
https://klse.i3investor.com/blogs/gloveharicut/2020-12-15-story-h1538222351-Kossan_briefing_update_from_RHB_Research.jsp
